通过巴里西丁尼布成功治疗子
Lluís Corbella-Bagot1, Miquel Sala2, Jaime Piquero-Casals3
1Department of Dermatology, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain.
International journal of trichology
|December 5, 2025
概括
与白发性脱发 (AA) 相关的突然头发变白 (canities subita) 显示,在巴里西提尼布治疗后,头发显著重新颜色化. 这表明巴里西提尼布作为潜在的治疗AA相关的癌症subita.
科学领域:
- 皮肤病学 皮肤病学
- 自免疫性疾病 自免疫性疾病
- 头发疾病 头发疾病
背景情况:
- Canities subita是一种罕见的突然脱发的罕见情况.
- 已经提出了canities subita和alopecia areata (AA) 之间的关联,但尚未完全确立.
研究的目的:
- 为了呈现一个案例的canitiessubita与同时发生的脱发.
- 评估巴里西提尼布在治疗这种综合性疾病中的疗效.
主要方法:
- 一个60岁的男性患有类风湿性关节炎的病例报告.
- 诊断的canitiessubita与并发的AA.
- 用巴里西提尼布治疗超过8个月.
主要成果:
- 患者经历了显著的头发再颜色化.
- 在尾部的脱发被逆转了.
- 这一结果支持了canities subita和AA之间的联系.
结论:
- 巴里西替尼 (baricitinib) 显示出作为治疗子病的潜力,特别是在与AA结合时.
- 需要进一步的研究来证实巴里西提尼布的疗效,并了解其在治疗犬病中的机制.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
413
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
413
Pulmonary Tuberculosis V
527
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
527
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450


